MON-146 Should We Treat All The Clinical Hypoestrogenic Disorders With Hormone Therapy?

Disclosure: C. Dominguez-Bali: None. D. Alame: None. S. Verma: None. C. Dos Santos: None. A. Dominguez-Bali: None. We would like to call attention to the possibility, as suggested by recent literature reviews, of using hormone therapy in a broader spectrum of conditions beyond just peri- and post-menopause. We have reviewed the literature as well as our personal and observational results in clinical practice with the use of hormone therapy in most hypoestrogenic disorders. We have observed positive responses in patients diagnosed with premenstrual dysphoric disorder, postpartum pseudo-menopause, postpartum blues, postpartum depression, postpartum dyspareunia, and exclusive breastfeeding-related dyspareunia treated with hormone therapy. Estradiol appears to be, by nature, an essential hormone for maintaining homeostasis and normal function in most of the body's cells and tissues. Its role is well established in the treatment and management of the various pathological manifestations of perimenopause and menopause—the most clearly defined hypoestrogenic states. But what about premenstrual syndrome, premenstrual dysphoric disorder, postpartum pseudo-menopause, or the now increasingly recognized worsening of ADHD symptoms in female patients during low-estrogen phases of the menstrual cycle? Postpartum blues and postpartum depression have traditionally been treated with antidepressants and anxiolytics, much like the depression seen in peri- and postmenopausal women. However, recent studies demonstrate clear benefits of estrogen use in the treatment of postpartum depression. Based on our literature review and our clinical observations using estrogen therapy, we suggest that conditions such as postpartum blues, postpartum depression, postpartum dyspareunia, exclusive breastfeeding-related dyspareunia, and even the cyclical worsening of ADHD symptoms merit consideration for hormone therapy.We now recognize that hormone therapy in these cases may be more effective, beneficial, and physiological. This presentation serves as a call for broader attention to the potential therapeutic benefits of hormone therapy in the management of these under-recognized hypoestrogenic disorders. Presentation: Monday, July 14, 2025